Please assess the completion status of the following clinical trial:

Trial Title: Cell Therapy in HFpEF

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Preserved left ventricular systolic function on echocardiography (LVEF\>50%)~* Evidence of diastolic dysfunction by echocardiography (E/e'\>15)~* Symptoms of heart failure~* NT-proBNP levels \>300 pg/ml~* absence of permanent atrial fibrillation~Exclusion Criteria:~* acute multi-organ failure~* history of any malignant disease within 5 years~* diminished functional capacity due to non-cardiac co-morbidities (COPD, PAOD, morbid obesity)~* pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- SC Group (Type: EXPERIMENTAL): In Phase 1 of the study, all patients will be treated with optimization of medical therapy for 6 months. Thereafter, all patients will cros over to Phase 2 of the study, where they will receive transendocardial CD34+ cell therapy. Follow-up of Phase 2 will last for 6 months. At the time of enrollment (6 months before cell therapy), at time of cell therapy, and 6 months thereafter we will perform detailed clinical evaluation, laboratory assays, echocardiography, 6-minute walk test, and measure plasma levels of N-terminal pro B-type natriuretic peptide (NT-proBNP).

Based on this trial design, predict the completion outcome and termination type (if applicable).